The Scientist : Table: Selected TLR Ligands in Clinical Trials

The Scientist
Volume 21 \| Issue 1 \| Page 49

Table: Selected TLR Ligands in Clinical Trials

Product	Target	Manufacturer	Condition	Phase	Intervention	Status
CPG7909	TLR9	Coley Pharmaceutical Group	Lymphoma	I/II	CpG injections and radiotherapy http://www.clinicaltrials.gov/ct/show/NCT00185965	Ongoing
ﾠ	ﾠ	Coley/Pfizer	Metastatic breast cancer, renal cell cancer, T-cell lymphoma, non-small cell lung cancer, melanoma	I or II	CpG injection with or without chemotherapy http://www.clinicaltrials.gov/ct/show/NCT00043407 http://www.clinicaltrials.gov/ct/show/NCT00043420 http://www.clinicaltrials.gov/ct/show/NCT00070629 http://www.clinicaltrials.gov/ct/show/NCT00070642	Ongoing and completed
ﾠ	ﾠ	ﾠ	Malaria	I	Malaria vaccine with and without CpG 7909 http://www.clinicaltrials.gov/ct/show/NCT00320658	Recruiting
CPG10101	TLR9	Coley Pharmaceutical Group	Hepatitis C	II	Pegylated interferon plus ribavirin with or without CPG 10101 in hepatitis C patients http://www.clinicaltrials.gov/ct/show/NCT00277238	Recruiting
ﾠ
1018 ISS	TLR9	Dynavax	Allergy	II	ISS conjugated to ragweed allergen given to patients with allergic rhinitis http://www.clinicaltrials.gov/ct/show/NCT00346086	Completed
ﾠ	ﾠ	ﾠ	B-cell follicular lymphoma	II	ISS given in conjunction with Rituxan http://www.clinicaltrials.gov/ct/show/NCT00251394	Recruiting
ﾠ	ﾠ	ﾠ	Metastatic colorectal cancer	I	ISS in combination with irinotecan and cetuximab http://www.clinicaltrials.gov/ct/show/NCT00403052	Recruiting
ﾠ	ﾠ	ﾠ	Hepatitis B	II	ISS with hepatitis B surface antigen compared with commercial hepatitis vaccine (completed in 2004; phase III trial underway in Asia)	Completed